Haemonetics (HAE) Misses Q4 EPS by 21c, Revenues Beat; Offers FY22 EPS Guidance Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts HAE Hot Sheet
Price: $120.28 +0.12%
EPS Growth %: +1.6%
Financial Fact:
Cost of goods sold: 116.01M
Today's EPS Names:
FUSE, INM, TRI, More
EPS Growth %: +1.6%
Financial Fact:
Cost of goods sold: 116.01M
Today's EPS Names:
FUSE, INM, TRI, More
Join SI Premium – FREE
Haemonetics (NYSE: HAE) reported Q4 EPS of $0.46, $0.21 worse than the analyst estimate of $0.67. Revenue for the quarter came in at $225 million versus the consensus estimate of $222.98 million.
GUIDANCE:
Haemonetics sees FY2022 EPS of $2.60-$3.00, versus the consensus of $2.56.
For earnings history and earnings-related data on Haemonetics (HAE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ultragenyx Pharma (RARE) Misses Q3 EPS by 6c; Offers Guidance
- Tarsus Pharmaceuticals, Inc. (TARS) Misses Q3 EPS by 1293c
- Essential Utilities, Inc. (WTRG) Tops Q3 EPS by 4c
Create E-mail Alert Related Categories
Corporate News, Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
